Stanford



Jay Shah

Associate Professor of Urology

CLINICAL OFFICE (PRIMARY)

- **Stanford Comprehensive Cancer Center**
  875 Blake Wilbur Dr Rm 2216
  MC 6560
  Stanford, CA 94305
  Tel (650) 725-5544 **Fax** (650) 736-7379

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**
  Kachyee Vang - Administrative Associate III
  Email vangk@stanford.edu
  Tel (650) 497-8753

Bio

BIO

Dr. Jay Shah, MD currently serves as Immediate Past Chief of the Medical Staff for Stanford Health Care. He is a cancer surgeon and associate professor of Urology at the Stanford University School of Medicine. His clinical focus is on bladder cancer, and he is well known for his expertise in robotic surgery. Since his arrival to Stanford, he has started the Urology Department Quality Program, the Urologic Oncology Fellowship, the Urology Resident Coaching Program, and the Inpatient Urology Hospitalist Program. His academic interests center on optimizing outcomes after bladder cancer treatment. He is very active in leadership development, team building, and quality improvement work and he lectures nationally and internationally on these topics. He is certified by the International Coaching Federation as an executive coach. He also serves as a Training Group facilitator for the highly popular course, Interpersonal Dynamics, at the Stanford Graduate School of Business.

Dr. Shah graduated from Harvard College, and he completed medical school and urology residency training at Columbia University. During his time at Columbia, Dr. Shah was elected to the Alpha Omega Alpha Medical Honor Society; he was named Physician of the Year by the nursing staff; and he was recognized by the medical students with the Gold Foundation Excellence in Teaching Award. After residency, he completed a three-year fellowship in Urologic Oncology at MD Anderson Cancer Center and then joined the faculty there. During his time at MD Anderson, Dr. Shah launched the bladder cancer robotics program, developed an enhanced recovery program for patients undergoing bladder removal surgery, became double board-certified in Urology and Medical Quality, and was chosen to lead the MDACC Genitourinary Center as Center Medical Director.

In his free time, Dr. Shah enjoys reading, cooking, growing his own food, surfing, and exploring the beaches of Northern California with his three dogs.

CLINICAL FOCUS

- Bladder cancer
- Robotic surgery
- Enhanced recovery after surgery (ERAS)
- Immunotherapy

- Urologic oncology
- Opioid-sparing strategies
- Urology

ACADEMIC APPOINTMENTS

- Associate Prof-Univ Med Line, Urology

ADMINISTRATIVE APPOINTMENTS

- Chief of Staff, Stanford Health Care, (2022-2026)
- Vice Chief of Staff, Stanford Health Care, (2020-2022)
- Clinic Advisory Council, Stanford Hospital, (2019- present)
- Committee on Professionalism, Stanford Hospital, (2020- present)
- Value-based Care Champion, Stanford University Department of Urology, (2020-2022)
- Physician Improvement Leader, Stanford University Department of Urology, (2017-2022)
- Genitourinary Cancer Care Program Leader, Stanford Cancer Center, (2017-2022)
- Center Medical Director, MDACC Genitourinary Center, (2016-2016)
- Member, American Urological Association International Academic Fellowship Committee, (2015- present)
- Director, MDACC Bladder Cancer Robotics Program, (2014-2016)
- Co-Quality Improvement Officer, MDCC Department of Urology, (2014-2016)
- Supervisor, MDACC Department of Urology Journal Club, (2012-2015)
- Director, MDACC Department of Urology Medical Student Education, (2010-2015)

HONORS AND AWARDS

- Stanford Medicine Leadership Academy, Stanford School of Medicine (2018-2019)
- Faculty, Clinical Effectiveness Leadership Training, Stanford Medicine (2018-2020)
- Stanford Leadership Development Program, Stanford Hospital (2017-2018)
- Clinical Effectiveness Leadership Training, Stanford Medicine (2017-2018)
- Distinguished Alumnus Award, Columbia University Department of Urology (2019)
- Leadership Academy, American Urological Association (2016-2017)
- Clinical Innovator Award, MD Anderson Cancer Center (2015-2017)
- Genitourinary SPORE Career Development Award, MD Anderson Cancer Center (2014-2016)
- Comparative Effectiveness Research on Cancer, Texas Scholar Award (2012-2014)
- Physician of the Year, Columbia University Medical Center (2006)
- Resident of the Year, Columbia University Department of Urology (2006)
- Humanism Honor Society Inductee, Arnold P. Gold Foundation (2006)
- Gerald P. Murphy Scholar, Ford Library and Museum (2006)
- Humanism and Excellence in Teaching Award, Columbia Medical School (2006)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Director, Stanford Health Care Board of Directors (2022 - 2026)

PROFESSIONAL EDUCATION

- Board Certification, Medical Quality , American Board of Medical Quality (2015)
- Healthcare Course, Harvard Business School Extension Program, Cambridge, MA , Value Measurement (2015)
- Board Certification: Urology, American Board of Urology (2012)
- Urologic Oncology Fellowship, MD Anderson Cancer Center, Houston, TX (2010)
- Fellowship: MD Anderson Cancer Center Urologic Oncology (2010) TX
- Urology Chief Residency, Columbia University Medical Center, New York, NY (2007)
- Urology Residency, Columbia University Medical Center, New York, NY (2006)
- General Surgery Internship, Columbia University Medical Center, New York, NY (2003)
- Medical Education: Columbia University College of Physicians and Surgeons (2002) NY
- BA in Biological Sciences, Harvard College, Cambridge, MA (1998)

Publications

PUBLICATIONS

- **The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy.** *Canadian Urological Association journal = Journal de l'Association des urologues du Canada*

  Ho, M. D., Black, A. J., Zargar, H., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., Krabbe, L. M., Cookson, M. S., Jacobsen, N. E., Montgomery, J. S., Yu, E. Y., Xylinas, et al

  2023; 17 (10): 301-309

- **A Leak in the System: Addressing the Environmental Impact of Urologic Care.** *European urology*

  Kornberg, Z., Wu, J., Wilmot, H., Duffina, T., Shah, J. B.

  2023

- **Multiphase preclinical assessment of a novel device to locate unintentionally retained surgical sharps: a proof-of-concept study.** *Patient safety in surgery*

  Kang, H. S., Khoraki, J., Gie, J., Duval, D., Haynes, S., Siev, M., Shah, J., Kim, F., Mangino, M., Procter, L., Autorino, R., Weprin, S.

  2023; 17 (1): 10

- **Association Between Antibiotic Prophylaxis Before Cystectomy or Stent Removal and Infection Complications: A Systematic Review.** *European urology focus*

  Antonelli, L., Sebro, K., Lahmar, A., Black, P. C., Ghodoussipour, S., Hamilton-Reeves, J. M., Shah, J., Bente Thoft, J., Lerner, S. P., Llorente, C., Lucca, I., Preston, M. A., Psutka, et al

  2023

- **Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer.** *World journal of urology*

  Einerhand, S. M., Black, A. J., Zargar, H., Fairey, A. S., Dinney, C. P., Mir, M. C., Krabbe, L. M., Cookson, M. S., Jacobson, N. E., Montgomery, J. S., Vasdev, N., Yu, E. Y., Xylinas, et al

  2022

- **Postoperative opioid-free ureteroscopy discharge: A quality initiative pilot protocol.** *Current urology*

  Kasman, A. M., Schmidt, B., Spradling, K., Chow, C., Hunt, R., Wu, M., Sockol, A., Liao, J., Leppert, J. T., Shah, J., Conti, S. L.

  2021; 15 (3): 176-180

- **Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle-Invasive Bladder Cancer.** *The Journal of urology*

  D'Andrea, D., Black, P. C., Zargar, H., Dinney, C. P., Soria, F., Cookson, M. S., Montgomery, J. S., Kassouf, W., Dall'Era, M. A., Sridhar, S. S., McGrath, J. S., Wright, J. L., Thorpe, et al

  2021: 101097JU0000000000002190

- **Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer.** *World journal of urology*

D'Andrea, D., Black, P. C., Zargar, H., Zargar-Shoshtari, K., Soria, F., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., Krabbe, L., Cookson, M. S., Jacobsen, N., Montgomery, et al
2021

- **Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers.** *Urologic oncology*
  Kukreja, J. B., Seif, M. A., Mery, M. W., Incalcaterra, J. R., Kamat, A. M., Dinney, C. P., Shah, J. B., Feeley, T. W., Navai, N.
  2020

- **Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.** *BJU international*
  Soria, F., Black, P. C., Fairey, A. S., Cookson, M. S., Yu, E. Y., Kassouf, W., Dall'Era, M. A., Sridhar, S. S., McGrath, J. S., Wright, J. L., Thorpe, A. C., Morgan, T. M., Daneshmand, et al
  2020

- **Critical Appraisal of Quality Improvement Publications in the Urological Literature** *UROLOGY PRACTICE*
  Greenberg, D. R., Sohlberg, E. M., Shkolyar, E., Shah, J. B.
  2020; 7 (5): 413–17

- **Critical Appraisal of Quality Improvement Publications in the Urological Literature.** *Urology practice*
  Greenberg, D. R., Sohlberg, E. M., Shkolyar, E., Shah, J. B.
  2020; 7 (5): 413-418

- **NEOADJUVANT CHEMOTHERAPY PLUS RADICAL CYSTECTOMY VERSUS RADICAL CYSTECTOMY IN CT2 BLADDER CANCER: A MULTICENTER STUDY**
  Giordano, A., Black, P., Fairey, A., Cookson, M., Yu, E., Kassouf, W., Dall'Era, M., Sridhar, S., McGrath, J., Wright, J., Thorpe, A., Morgan, T., Daneshmand, et al
  INT INST ANTICANCER RESEARCH.2020: 4636–37

- **The Impact of Early Exposure to Urology: Evaluation of an Introductory Preclinical Course** *UROLOGY PRACTICE*
  Greenberg, D. R., Conti, S. L., Shah, J. B.
  2020; 7 (4): 322–27

- **Reply by Authors.** *Urology practice*
  Greenberg, D. R., Conti, S. L., Shah, J. B.
  2020; 7 (4): 328

- **The Impact of Early Exposure to Urology: Evaluation of an Introductory Preclinical Course.** *Urology practice*
  Greenberg, D. R., Conti, S. L., Shah, J. B.
  2020; 7 (4): 322-328

- **Clinical -Bladder cancer Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer** *UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS*
  D'Andrea, D., Black, P. C., Zargar, H., Zargar-Shoshtari, K., Zehetmayer, S., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., Krabbe, L., Cookson, M. S., Jacobsen, N., Montgomery, et al
  2020; 38 (7)

- **Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer.** *Urologic oncology*
  Bhambhvani, H. P., Zamora, A., Shkolyar, E., Prado, K., Greenberg, D. R., Kasman, A. M., Liao, J., Shah, S., Srinivas, S., Skinner, E. C., Shah, J. B.
  2020

- **POST-OPERATIVE OPIOID FREE URETEROSCOPY: A PROTOCOL PILOT STUDY**
  Kasman, A., Schmidt, B., Spradling, K., Chow, C., Wu, M., Hunt, R., Sockol, A., Smith, H., Shah, J., Conti, S.
  LIPPINCOTT WILLIAMS & WILKINS.2020: E162

- **Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes.** *Urologic oncology*
  Narayan, V. M., Seif, M. A., Lim, A. H., Li, R., Matulay, J. T., Kukreja, J. B., Qiao, W., Hwang, H., Shah, J. B., Pisters, L., Kamat, A. M., Dinney, C., Navai, et al
  2020

- **Bupivacaine local anesthetic to decrease opioid requirements after radical cystectomy: Does formulation matter?** *Urologic oncology*

Schmidt, B. n., Bhambhvani, H. P., Greenberg, D. R., Prado, K. n., Shafer, S. n., Thong, A. n., Gill, H. n., Skinner, E. n., Shah, J. B.
2020

- **Implementation of a Reduced Opioid Utilization Protocol for Radical Cystectomy** *BLADDER CANCER*
  Greenberg, D. R., Kee, J. R., Stevenson, K., Van Zyl, E., Dugala, A., Prado, K., Gill, H. S., Skinner, E. C., Shah, J. B.
  2020; 6 (1): 33–42

- **Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer.** *Urologic oncology*
  D'Andrea, D. n., Black, P. C., Zargar, H. n., Zargar-Shoshtari, K. n., Zehetmayer, S. n., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., Krabbe, L. M., Cookson, M. S., Jacobsen, N. E., Montgomery, et al
  2020

- **The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.** *Urologic oncology*
  Black, A. J., Zargar, H., Zargar-Shoshtari, K., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., Krabbe, L., Cookson, M. S., Jacobsen, N., Griffin, J., Montgomery, J. S., Vasdev, et al
  2019

- **IMPLEMENTATION OF A REDUCED OPIOID UTILIZATION PROTOCOL FOR RADICAL CYSTECTOMY**
  Greenberg, D., Kee, J., Stevenson, K., Van Zyl, E., Dugala, A., Prado, K., Gill, H., Skinner, E., Shah, J.
  LIPPINCOTT WILLIAMS & WILKINS.2019: E1196–E1197

- **ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer** *WORLD JOURNAL OF UROLOGY*
  Monteiro, L. L., Witjes, J., Agarwal, P. K., Anderson, C. B., Bivalacqua, T. J., Bochner, B. H., Boormans, J. L., Chang, S. S., Dominguez-Escrig, J. L., McKiernan, J. M., Dinney, C., Godoy, G., Kulkarni, et al
  2019; 37 (1): 51–60

- **Reducing opioid utilization after urologic oncology surgery.**
  Stevenson, K., Kee, J., Van Zyl, E., Dugala, A., Shah, J.
  AMER SOC CLINICAL ONCOLOGY.2018

- **Neurocognitive deficits in older patients with cancer.** *Journal of geriatric oncology*
  Edwards, B. J., Zhang, X., Sun, M., Holmes, H. M., Ketonen, L., Guha, N., Khalil, P., Song, J., Kesler, S., Shah, J. B., Tripathy, D., Valero, V., Champlin, et al
  2018; 9 (5): 482-487

- **Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.** *European urology focus*
  Kukreja, J. B., Porten, S., Golla, V., Ho, P. L., Noguera-Gonzalez, G., Navai, N., Kamat, A. M., Dinney, C. P., Shah, J. B.
  2018; 4 (5): 720-724

- **Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy** *BJU INTERNATIONAL*
  Mmeje, C. O., Benson, C. R., Nogueras-Gonzalez, G. M., Jayaratna, I. S., Gao, J., Siefker-Radtke, A. O., Kamat, A. M., Dinney, C. P., Navai, N., Shah, J. B.
  2018; 122 (1): 89–98

- **Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy** *JOURNAL OF UROLOGY*
  Zargar, H., Shah, J. B., van Rhijn, B. W., Daneshmand, S., Bivalacqua, T. J., Spiess, P. E., Black, P. C., Kassouf, W.
  2018; 199 (6): 1453–59

- **Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy**
  Kukreja, J., Shi, Q., Chang, C. M., Seif, M. A., Sterling, B. M., Chen, T., Creel, K. M., Kamat, A. M., Dinney, C. P., Navai, N., Shah, J. B., Wang, X.
  SAGE PUBLICATIONS INC.2018: 242–50

- **Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study** *JOURNAL OF UROLOGY*
  Daneshmand, S., Patel, S., Lotan, Y., Pohar, K., Trabulsi, E., Woods, M., Downs, T., Huang, W., Jones, J., O'Donnell, M., Bivalacqua, T., DeCastro, J., Steinberg, et al

2018; 199 (5): 1158–86

- **Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience.** *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*
  Edwards, B. J., Sun, M., Zhang, X., Holmes, H. M., Song, J., Khalil, P., Karuturi, M., Shah, J. B., Dinney, C. P., Gagel, R. F., Valero, V., Champlin, R. E., Tripathy, et al
  2018; 26 (5): 1561-1568

- **Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index.** *Journal of geriatric oncology*
  Zhang, X., Sun, M., McKoy, J. M., Bhulani, N. N., Valero, V., Barcenas, C. H., Popat, U. R., Sri, M. K., Shah, J. B., Dinney, C. P., Hedberg, A. M., Champlin, R., Tripathy, et al
  2018; 9 (1): 81-83

- **Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study** *CLINICAL GENITOURINARY CANCER*
  Haddad, A. Q., Hutchinson, R., Wood, E. L., Miranda, G., Gershman, B., Messer, J., Svatek, R., Black, P. C., Boorjian, S. A., Shah, J., Daneshmand, S., Lotan, Y.
  2017; 15 (6): 689-+

- **Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study.** *Clinical genitourinary cancer*
  Haddad, A. Q., Hutchinson, R., Wood, E. L., Miranda, G., Gershman, B., Messer, J., Svatek, R., Black, P. C., Boorjian, S. A., Shah, J., Daneshmand, S., Lotan, Y.
  2017; 15 (6): 689-695.e2

- **Dose dense MVAC prior to radical cystectomy: a real-world experience.** *World journal of urology*
  Zargar, H., Shah, J. B., van de Putte, E. E., Potvin, K. R., Zargar-Shoshtari, K., van Rhijn, B. W., Daneshmand, S., Holzbeierlein, J. M., Spiess, P. E., Winquist, E., Horenblas, S., Dinney, C., Black, et al
  2017; 35 (11): 1729-1736

- **Risk of hospitalisation after primary treatment for prostate cancer.** *BJU international*
  Williams, S. B., Duan, Z., Chamie, K., Hoffman, K. E., Smith, B. D., Hu, J. C., Shah, J. B., Davis, J. W., Giordano, S. H.
  2017; 120 (1): 48-55

- **Advances in surgical management of muscle invasive bladder cancer.** *Indian journal of urology : IJU : journal of the Urological Society of India*
  Kukreja, J. B., Shah, J. B.
  2017; 33 (2): 106-110

- **Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer.** *BJU international*
  Fernández, M. I., Williams, S. B., Willis, D. L., Slack, R. S., Dickstein, R. J., Parikh, S., Chiong, E., Siefker-Radtke, A. O., Guo, C. C., Czerniak, B. A., McConkey, D. J., Shah, J. B., Pisters, et al
  2017; 119 (5): 684-691

- **Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guerin Therapy: Implication for Clinical Trial Design** *EUROPEAN UROLOGY*
  Mmeje, C. O., Guo, C. C., Shah, J. B., Navai, N., Grossman, H. B., Dinney, C. P., Kamat, A. M.
  2016; 70 (5): 778-785

- **Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer.** *Annals of surgical oncology*
  Navai, N., Benedict, W. F., Zhang, G., Abraham, A., Ainslie, N., Shah, J. B., Grossman, H. B., Kamat, A. M., Dinney, C. P.
  2016; 23 (12): 4110-4114

- **The Future of Enhanced Recovery for Radical Cystectomy: Current Evidence, Barriers to Adoption, and the Next Steps.** *Urology*
  Danna, B. J., Wood, E. L., Baack Kukreja, J. E., Shah, J. B.
  2016; 96: 62-68

- **Assessing Symptom Burden in Bladder Cancer: An Overview of Bladder Cancer Specific Health-Related Quality of Life Instruments.** *Bladder cancer (Amsterdam, Netherlands)*
  Danna, B. J., Metcalfe, M. J., Wood, E. L., Shah, J. B.
  2016; 2 (3): 329-340

- **Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance.** *BJU international*
  Davis, J. W., Ward, J. F., Pettaway, C. A., Wang, X., Kuban, D., Frank, S. J., Lee, A. K., Pisters, L. L., Matin, S. F., Shah, J. B., Karam, J. A., Chapin, B. F., Papadopoulos, et al
  2016; 118 (1): 68-76

- **Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy.** *World journal of urology*
  Zargar-Shoshtari, K., Zargar, H., Dinney, C. P., Ercole, C. E., Sharma, P., Kovac, E., Grivas, P. D., Stephenson, A. J., Shah, J. B., Black, P. C., Spiess, P. E.
  2016; 34 (5): 695-701

- **Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank.** *Bladder cancer (Amsterdam, Netherlands)*
  Kamat, A. M., Agarwal, P., Bivalacqua, T., Chisolm, S., Daneshmand, S., Doroshow, J. H., Efstathiou, J. A., Galsky, M., Iyer, G., Kassouf, W., Shah, J., Taylor, J., Williams, et al
  2016; 2 (2): 203-213

- **Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1?** *The Journal of urology*
  Zargar, H., Zargar-Shoshtari, K., Lotan, Y., Shah, J. B., van Rhijn, B. W., Daneshmand, S., Spiess, P. E., Black, P.
  2016; 195 (4 Pt 1): 886-93

- **Association between Perioperative Blood Transfusions and Clinical Outcomes in Patients Undergoing Bladder Cancer Surgery: A Systematic Review and Meta-Analysis Study.** *Journal of blood transfusion*
  Cata, J. P., Lasala, J., Pratt, G., Feng, L., Shah, J. B.
  2016; 2016: 9876394-?

- **A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy.** *The Journal of urology*
  Zargar-Shoshtari, K., Zargar, H., Lotan, Y., Shah, J. B., van Rhijn, B. W., Daneshmand, S., Spiess, P. E., Black, P. C.
  2016; 195 (1): 53-9

- **Is Exam under Anesthesia Still Necessary for the Staging of Bladder Cancer in the Era of Modern Imaging?** *Bladder cancer (Amsterdam, Netherlands)*
  Rozanski, A. T., Benson, C. R., McCoy, J. A., Green, C., Grossman, H. B., Svatek, R. S., Shah, J. B.
  2015; 1 (1): 91-96

- **Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.** *European urology*
  Zargar, H., Espiritu, P. N., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., Krabbe, L. M., Cookson, M. S., Jacobsen, N. E., Gandhi, N. M., Griffin, J., Montgomery, J. S., Vasdev, et al
  2015; 67 (2): 241-9

- **Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy.** *Urology*
  Svatek, R. S., Clinton, T. N., Wilson, C. A., Kamat, A. M., Grossman, H. B., Dinney, C. P., Shah, J. B.
  2014; 84 (5): 1147-51

- **Physician variation in management of low-risk prostate cancer: a population-based cohort study.** *JAMA internal medicine*
  Hoffman, K. E., Niu, J., Shen, Y., Jiang, J., Davis, J. W., Kim, J., Kuban, D. A., Perkins, G. H., Shah, J. B., Smith, G. L., Volk, R. J., Buchholz, T. A., Giordano, et al
  2014; 174 (9): 1450-9

- **Multi-institutional quality care initiative (QCI) to improve the care of patients with invasive bladder cancer (BICa).**
  Bochner, B. H., Feifer, A., Sperling, D., Mashni, J. W., Bajorin, D. F., Shah, J., Kamat, A. M., Steinberg, G. D., Stadler, W., Grubb, R. L., Kibel, A. S., Schoenberg, M., Black, et al
  AMER SOC CLINICAL ONCOLOGY.2014

- **Hiding in Plain View: Genetic Profiling Reveals Decades Old Cross Contamination of Bladder Cancer Cell Line KU7 with HeLa** *JOURNAL OF UROLOGY*
  Jaeger, W., Horiguchi, Y., Shah, J., Hayashi, T., Awrey, S., Gust, K. M., Hadaschik, B. A., Matsui, Y., Anderson, S., Bell, R. H., Ettinger, S., So, A. I., Gleave, et al

2013; 190 (4): 1404-1409

- **Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center.** *European urology*
  Lynch, S. P., Shen, Y., Kamat, A., Grossman, H. B., Shah, J. B., Millikan, R. E., Dinney, C. P., Siefker-Radtke, A.
  2013; 64 (2): 307-13

- **Strategies for optimizing bacillus Calmette-Guérin.** *The Urologic clinics of North America*
  Shah, J. B., Kamat, A. M.
  2013; 40 (2): 211-8

- **Demographic analysis of randomized controlled trials in bladder cancer** *BJU INTERNATIONAL*
  Bachir, B. G., Shariat, S. F., Zlotta, A., Svatek, R., Black, P. C., Shah, J. B., Kassouf, W., Bladder Canc Think Tank Bladder, Canadian Bladder Canc Network
  2013; 111 (3): 419-426

- **Robot-assisted extended pelvic lymph node dissection (PLND) at the time of radical prostatectomy (RP): a video-based illustration of technique, results, and unmet patient selection needs.** *BJU international*
  Davis, J. W., Shah, J. B., Achim, M.
  2011; 108 (6 Pt 2): 993-8

- **New strategies in muscle-invasive bladder cancer: on the road to personalized medicine.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
  Shah, J. B., McConkey, D. J., Dinney, C. P.
  2011; 17 (9): 2608-12

- **Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.** *Urologic oncology*
  Inamoto, T., Shah, J. B., Kamat, A. M.
  2009; 27 (6): 585-91

- **Prostate biopsy patterns in the CaPSURE database: evolution with time and impact on outcome after prostatectomy.** *The Journal of urology*
  Shah, J. B., McKiernan, J. M., Elkin, E. P., Carroll, P. R., Meng, M. V.
  2008; 179 (1): 136-40

- **Water under the bridge: 5-year outcomes after percutaneous ablation of obstructing parapelvic renal cysts.** *Journal of endourology*
  Shah, J. B., Whitman, C., Lee, M., Gupta, M.
  2007; 21 (10): 1167-70

- **Changes in prognostic significance and predictive accuracy of Gleason grading system throughout PSA era: Impact of grade migration in prostate cancer** *UROLOGY*
  Mitchell, R. E., Shah, J. B., Desai, M., Mansukhani, M. M., Olsson, C. A., Benson, M. C., McKiernan, J. M.
  2007; 70 (4): 706-710

- **New treatments for superficial bladder cancer.** *Current oncology reports*
  Shah, J. B., Badalato, G. M., McKiernan, J. M.
  2006; 8 (3): 201-5

- **Preoperative serum prostate specific antigen remains a significant prognostic variable in predicting biochemical failure after radical prostatectomy** *JOURNAL OF UROLOGY*
  Mitchell, R. E., Desai, M., Shah, J. B., Olsson, C. A., Benson, M. C., McKiernan, J. M.
  2006; 175 (5): 1663-1667

- **Does year of radical prostatectomy independently predict outcome in prostate cancer?** *Urology*
  Mitchell, R. E., Shah, J. B., Olsson, C. A., Benson, M. C., McKiernan, J. M.
  2006; 67 (2): 368-72

- **Hypogonadism and metabolic syndrome: implications for testosterone therapy.** *The Journal of urology*
  Makhsida, N., Shah, J., Yan, G., Fisch, H., Shabsigh, R.
  2005; 174 (3): 827-34

- **PSA updated: Still relevant in the new millennium?** *EUROPEAN UROLOGY*

Shah, J. B., Reese, A. C., McKiernan, J. M., Benson, M. C.
2005; 47 (4): 427-432

- **Novel therapeutics in the treatment of bladder cancer.** *Current opinion in urology*
  Shah, J. B., McKiernan, J. M.
  2004; 14 (5): 287-93
- **A survey of US medical education in otolaryngology** *ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY*
  Haddad, J., Shah, J., Takoudes, T. G.
  2003; 129 (11): 1166-1169
- **The role of free radicals in chronic rhinosinusitis.** *Archives of otolaryngology--head & neck surgery*
  Friedman, A. D., Shah, J. B., Takoudes, T. G., Haddad, J.
  2002; 128 (9): 1055-7

PRESENTATIONS

- Implementation of ERAS for Patients Undergoing Radical Cystectomy - Adyar Cancer Institute (February 22, 2020)
- This is How Radical Cystectomy Should be Done in 2020 - TATA Memorial Hospital (February 29, 2020)
- TURBT Technique: Glimpses from a Surgeon's Collection - Tata Memorial Hospital (February 29, 2020)
- Adaptive Leadership for Emerging Healthcare Leaders - USC Healthcare Leadership Academy (January 10, 2020)
- Leadership Skills for Quality Improvement Work - Kenya Quality Improvement Collaborative (June 10, 2019)
- Leadership Skills for Fellows - Stanford University Department of Obstetrics & Gynecology Fellowship Program (January 27, 2020)
- Leading from the Heart - USC Healthcare Leadership Academy (January 11, 2019)
- Everyday Leadership for Physicians - Large Urology Group Practice Association (November 4, 2018)